secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
CIK:        0001757499
Form:       8-K
Filed at:   2024-10-28T23:59:59+00:00
Accession:  0001493152-24-042614
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CEO to present at ThinkEquity Conference; updates on Phase 2 glioblastoma trial and diagnostics
--------------------------------------------------------------------------------

- CEO Dr. Anatoly Dritschilo will present at ThinkEquity Conference on Oct 30, 2024 at 8:30am ET.
- Presentation covers Phase 2 trial of Ropidoxuridine for glioblastoma; no new data disclosed.
- Update on Shuttle Diagnostics subsidiary: predictive biomarkers for prostate cancer and PSMA ligand.
- Company posted updated investor presentation on its website; one-on-one meetings available.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1757499/000149315224042614/0001493152-24-042614-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1757499/000149315224042614/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-042614

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer